Expression of Sox2 in Human Ovarian Epithelial Carcinoma

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2010 Mar 30

PMID 20349085

Citations 33

Authors

Feng Ye

Yanli Li

Ying Hu

Caiyun Zhou

Yuting Hu

Huaizeng Chen

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of this study was to investigate the expression of Sox2, a transcription factor, in a series of benign, borderline, and malignant ovarian tumors and to evaluate whether Sox2 expression levels correlate with clinicopathological characteristics in ovarian epithelial carcinoma.

Methods: This study investigated immunohistochemical expressions of Sox2 in 43 species of normal ovarian epithelia, 284 species of serous epithelial lesions, and 164 species of mucinous epithelial lesions to assess their clinicopathological relevance.

Results: Immunohistochemical results showed that the positive ratio of Sox2 expression gradually increased from benign and borderline to malignant ovarian tumors; 55.81% of normal ovarian epithelia, ~65% of serous and mucinous cystadenoma, ~70% of borderline serous and mucinous cystadenoma, and ~91% of serous and mucinous cystadenocarcinoma expressed Sox2, respectively. However, there was no significant correlation between Sox2 expression and the age and level of CA125 in patients with either serous or mucinous tumors. Positive correlations between Sox2 expression levels and FIGO stage or pathological stage were identified in both serous and mucinous cystadenocarcinoma samples.

Conclusion: The expression level of Sox2 in human ovarian tumors was directly proportional to their degree of malignancy, implying that Sox2 overexpression may be closely related to the malignant transformation of ovarian tumors.

Citing Articles

The relationship of immunohistochemical SOX-2 staining with histopathological diagnosis in patients with abnormal colposcopic findings.

Atigan A, Kilic D, Karakaya Y, Gok S, Guler O Histochem Cell Biol. 2023; 160(6):555-561.

PMID: 37558931 DOI: 10.1007/s00418-023-02230-4.

Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets.

Alatise K, Gardner S, Alexander-Bryant A Cancers (Basel). 2022; 14(24).

PMID: 36551731 PMC: 9777152. DOI: 10.3390/cancers14246246.

Mesothelin Expression Is Not Associated with the Presence of Cancer Stem Cell Markers SOX2 and ALDH1 in Ovarian Cancer.

Nunes M, Pacheco F, Coelho R, Leitao D, Ricardo S, David L Int J Mol Sci. 2022; 23(3).

PMID: 35162954 PMC: 8834752. DOI: 10.3390/ijms23031016.

Establishment of a New Cell Line of Canine Mammary Tumor CMT-1026.

Mei C, Xin L, Liu Y, Lin J, Xian H, Zhang X Front Vet Sci. 2021; 8:744032.

PMID: 34712723 PMC: 8546253. DOI: 10.3389/fvets.2021.744032.

High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.

Wang H, Ye F, Zhou C, Cheng Q, Chen H PLoS One. 2021; 16(2):e0245733.

PMID: 33635867 PMC: 7909685. DOI: 10.1371/journal.pone.0245733.

References

van der Burg M . Advanced ovarian cancer. Curr Treat Options Oncol. 2002; 2(2):109-18. DOI: 10.1007/s11864-001-0053-1. View

Taranova O, Magness S, Fagan B, Wu Y, Surzenko N, Hutton S . SOX2 is a dose-dependent regulator of retinal neural progenitor competence. Genes Dev. 2006; 20(9):1187-202. PMC: 1472477. DOI: 10.1101/gad.1407906. View

Sinclair A, Berta P, Palmer M, Hawkins J, GRIFFITHS B, Smith M . A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature. 1990; 346(6281):240-4. DOI: 10.1038/346240a0. View

Ellis P, Fagan B, Magness S, Hutton S, Taranova O, Hayashi S . SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev Neurosci. 2005; 26(2-4):148-65. DOI: 10.1159/000082134. View

Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y . Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009; 16(12):3488-98. DOI: 10.1245/s10434-009-0617-z. View

Kiernan A, Pelling A, Leung K, Tang A, Bell D, Tease C . Sox2 is required for sensory organ development in the mammalian inner ear. Nature. 2005; 434(7036):1031-5. DOI: 10.1038/nature03487. View

Santagata S, Ligon K, Hornick J . Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007; 31(6):836-45. DOI: 10.1097/PAS.0b013e31802e708a. View

Canevari S, Gariboldi M, Reid J, Bongarzone I, Pierotti M . Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol. 2006; 60(1):19-37. DOI: 10.1016/j.critrevonc.2006.03.003. View

Schepers G, Teasdale R, Koopman P . Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell. 2002; 3(2):167-70. DOI: 10.1016/s1534-5807(02)00223-x. View

10.

Swart A, Burdett S, Ledermann J, Mook P, Parmar M . Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. Ann Oncol. 2007; 19(4):688-95. DOI: 10.1093/annonc/mdm518. View

11.

Sankaranarayanan R, Ferlay J . Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2005; 20(2):207-25. DOI: 10.1016/j.bpobgyn.2005.10.007. View

12.

Rex M, Church R, Tointon K, Ichihashi R, Mokhtar S, Uwanogho D . Granule cell development in the cerebellum is punctuated by changes in Sox gene expression. Brain Res Mol Brain Res. 1998; 55(1):28-34. DOI: 10.1016/s0169-328x(97)00354-9. View

13.

Wegner M . From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res. 1999; 27(6):1409-20. PMC: 148332. DOI: 10.1093/nar/27.6.1409. View

14.

Li X, Eishi Y, Bai Y, Sakai H, Akiyama Y, Tani M . Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol. 2004; 24(2):257-63. View

15.

Pevny L, Placzek M . SOX genes and neural progenitor identity. Curr Opin Neurobiol. 2005; 15(1):7-13. DOI: 10.1016/j.conb.2005.01.016. View

16.

Sholl L, Long K, Hornick J . Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol. 2009; 18(1):55-61. DOI: 10.1097/PAI.0b013e3181b16b88. View

17.

McCluggage W, Young R . Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol. 2006; 22(1):3-32. DOI: 10.1053/j.semdp.2005.11.002. View

18.

Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Munsterberg A . A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature. 1990; 346(6281):245-50. DOI: 10.1038/346245a0. View

19.

Park E, Gum J, Kakar S, Kwon S, Deng G, Kim Y . Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions. Int J Cancer. 2007; 122(6):1253-60. DOI: 10.1002/ijc.23225. View

20.

Chobanian N, Dietrich 3rd C . Ovarian cancer. Surg Clin North Am. 2008; 88(2):285-99, vi. DOI: 10.1016/j.suc.2007.12.002. View